Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751577 | 0.94 | ALDH1A1 (0.62) | ALDH1A1RECQLCNR2PKMKDM4E | |
| SCHEMBL6710583 | 0.85 | ALDH1A1 (0.69) | ALDH1A1RECQLPKMKDM4EMAPK1 | |
| SCHEMBL6191784 | 0.84 | ALDH1A1 (0.46) | ALDH1A1RECQLMEP1AMEP1BFFAR1 | |
| SCHEMBL6774685 | 0.83 | ALDH1A1 (0.73) | ALDH1A1RECQLPKMKDM4EMAPK1 | |
| SCHEMBL5861624 | 0.81 | ALDH1A1 (0.71) | ALDH1A1RECQLPKMKDM4EMAPK1 | |
| SCHEMBL30655553 | 0.81 | ALDH1A1 (0.71) | ALDH1A1RECQLPKMKDM4EMAPK1 | |
| SCHEMBL627157 | 0.81 | ALDH1A1 (0.71) | ALDH1A1RECQLPKMKDM4EMAPK1 | |
| SCHEMBL6295221 | 0.81 | ALDH1A1 (0.71) | ALDH1A1RECQLPKMKDM4EMAPK1 | |
| SCHEMBL27395266 | 0.81 | ALDH1A1 (1.00) | ALDH1A1RECQLPKMKDM4EMAPK1 | |
| SCHEMBL6775301 | 0.81 | ALDH1A1 (0.70) | ALDH1A1RECQLPKMKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903128-B2 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2004-05-27 | — | — | US | disclosed |
| US-6699895-B2 | CYCLIZING THE TERT-BUTYL-THIOUREA DERIVATIVE TO FORM THE END PRODUCT | AVENTIS PHARMA S.A. (FR) | 2004-03-02 | — | — | US | disclosed |
| US-6668527-B2 | Antiinflamamtory agents; autoimmune disease | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-6667331-B2 | For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )-3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| US-6608204-B1 | Peptide aldehyde having arginine or arginine mimics at P1 and pyridone, pyrimidone, or uracil groups; antithrombosis agents | CORVAS INTERNATIONAL, INC. | 2003-08-19 | — | — | US | disclosed |
| US-6576613-B1 | Arginine derivatives; monitoring plasminogen activator levels; inhibiting angiogenesis and tumor cell growth | CORVAS INTERNATIONAL, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-05-29 | — | — | US | disclosed |
| EP-0885186-B1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | THOMAE GMBH DR K (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-01-02 | — | — | US | disclosed |
| WO-1997019911-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
| EP-0765338-A1 | ARGININE MIMIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0765339-A1 | 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | disclosed |
| WO-1996018644-A9 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | — | 1996-08-01 | — | — | WO | disclosed |
| WO-1996018644-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995035313-A1 | 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| WO-1995035312-A1 | ARGININE MIMIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0680469-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017035-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, CCR10 | ALDH1A1 1669/4885RECQL 4305/4885CNR2 649/4885 |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, VSIG8 | ALDH1A1 1657/4885RECQL 4392/4885CNR2 593/4885 |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELP, SELPLG | ALDH1A1 1255/4885RECQL 4695/4885CNR2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.